CT导向氩氦刀冷冻治疗肺部肿瘤影像学表现研究

目的研究CT导向经皮穿刺氩氦刀靶向治疗肺部肿瘤后影像学变化,临床疗效及预后。方法CT引导经皮肺穿刺氩氦刀靶向治疗肺癌及肺转移瘤96例。结果96例中,肺癌82例,肺转移瘤14例,共110个病灶。氩氦刀共治疗103次,平均每次治疗1.06个病灶。肿瘤直径1.2~15cm,平均(4.0±2.5)cm。直径<4cm的肺内63个肿块显效率100%,直径4~6cm的肺内24个肿块,显效率95.8%,直径>6cm的23个肺内肿块,显效率69.6%。肺部肿瘤冷冻后CT表现病灶处开始可见逐渐增大的低密度类圆形冷冻区,冷冻区中心CT值为负值。随着氩氦刀冷冻治疗后时间延续,大部分肿块较前比较有不同程度的缩小或消失,P<0.001。术后12月CT追踪了81个病灶,肿块完全消失(CR)16个(19.8%),缩小(PR)42个(51.9%),稳定(NC)17个(21%),增大(PD)6个(7.4%),总有效率为92.6%。结论CT检查对肺部肿瘤氩氦刀靶向治疗后疗效的评价及预后判断有重要参考价值。     

CT引导下经皮穿刺化学消融术治疗腹膜后淋巴结转移瘤的疗效

 目的 探讨CT引导下经皮穿刺化学消融术治疗腹膜后淋巴结转移瘤的疗效。方法 回顾性分析CT引导下经皮细针穿刺化学消融术治疗28例腹膜后淋巴结转移瘤患者的临床资料,其中原发病灶为肝癌12例,胃癌10例,胰腺癌3例,结肠癌3例(共31个病灶)。采用22G Chiba针穿刺,制备化学消融剂[无水乙醇(18 ml)、聚桂醇(2 ml)、碘化油(2 ml)、洛铂(10 mg)、表阿霉素(10 mg)按9∶1∶1∶3∶3比例制成混悬液],术后1、3、6、12个月复查增强CT,评价肿瘤体积缩小及坏死情况,采用VAS评分评价疼痛缓解情况,随访时间为12个月。结果 28例(31个病灶)手术均获得成功,术中及术后无严重不良反应。治疗前VAS评分为(6.3±1.5)分,治疗后1个月VAS评分为(1.3±1.2)分(t=13.773,P<0.05);治疗前病灶最大径为(4.2±0.8)cm,治疗后12个月病灶最大径为(1.7±0.5)cm(t=14.755,P<0.05)。结论 CT引导下经皮穿刺化学消融术治疗腹膜后淋巴结转移瘤是一种效果显著的介入方法,其远期疗效和对患者生存期的影响还有待进一步的研究。     

CT导向下周围型肺癌射频消融治疗的临床分析

目的 探讨CT导向下射频消融（RFA）治疗周围型肺癌的价值。方法 43例周围型肺癌进行了CT导向下射频消融治疗。术前常规CT导向下经皮穿刺活检获取病理学诊断，鳞癌15例，腺癌19例，腺鳞癌4例，大细胞癌3例，未分化癌2例。全部瘤体直径均〈8cm，其中32个病灶直径〈5cm。结果 全部病例手术顺利，术中并发少量气胸者3例，液气胸1例，大量气胸行闭式引流者1例。术后分别在3和6个月CT复查，显示43个病灶中40个体积均有不同程度的进行性缩小，肿瘤内部均出现大片不规则低密度区；3例患者病灶体积无变化，边缘有环状强化，提示肿瘤复发。结论 CT导向下经皮穿刺RFA治疗周围型肺癌是安全有效的微创技术，值得推广应用。     

肺部肿瘤CT导向氩氦刀冷冻治疗前后的影像表现

目的研究CT导向经皮肺穿刺氩氦刀靶向治疗肺部肿瘤前后的影像表现及临床疗效评价。方法对96例肺部肿瘤患者采用CT引导下经皮肺穿刺氩氦刀靶向治疗。所有患者术前、术后均行CT扫描，测定肿瘤大小及CT值，并分别于术后1、3、6、12个月复查CT。结果原发肺癌82例，肺转移瘤14例，共110个病灶，单病灶89例，多病灶7例。氩氦刀共治疗103次，平均每次治疗1.07个病灶。每次最多治疗3个病灶。肿瘤直径1.2～15.0cm，平均（4.0±2.5）cm。其中瘤灶直径〈2cm12个，≥2～4cm51个，≥4～6cm24个，〉6cm23个。冰球彻底覆盖瘤灶达其边缘外1am者25例。肿块直径〈4am的63个，有效率为100％，≥4～6am的有效率为95．8％（23／24），〉6am的有效率为69．6％（16／23）。肺部肿瘤冷冻后CT可见逐渐增大的低密度类圆形冷冻区，与非冷冻区有明显的界限。冷冻区中心CT值为负值，术后即刻CT值平均下降30～50HU，与术前CT值相比差异有统计学意义（P〈0．01）。氩氦刀冷冻治疗前后肿瘤直径比较，差异有统计学意义（P〈0．05）。直径〈2cm的病灶治疗3个月后均已消失。术后12个月CT复查81个被消融肿块，完全消失16个（19．7％），缩小42个（51．9％），稳定17个（21．0％），增大6个（7．4％），总有效率为92．6％。43个鳞癌和28个腺癌经氩氦刀治疗12个月后疗效差异无统计学意义（X^2=0.05，P〉0.05）。结论肺部肿瘤氩氦刀冷冻治疗后CT影像表现对其疗效的评价有重要参考价值。     

集束电极射频治疗肺癌效果的CT评估

目的　CT评价集束电极射频治疗肺癌的近期疗效。方法　对 6 8例肺癌患者通过集束电极射频治疗用CT比较手术前后肿瘤大小和密度的变化。结果　 6 8例肺癌 70个病灶射频治疗术前、术后 30min和术后 6 0d进行CT复查。单点治疗组 :病灶的体积在术后 30min增大明显 ,在术后 6 0d缩小 ,治疗前后病灶最大径分别为 (4.15± 0 .97)cm ,(5 .5 4± 1.37)cm和 (2 .79± 0 .6 8)cm ,有显著性差异 (P <0 .0 5 )。多点治疗组 :病灶的体积在 30min增加不显著 ,在 6 0d缩小不明显 ,病灶最大径分别为 (8.0 6±1.91)cm ,(9.13± 1.78)cm和 (7.6 3± 2 .16 )cm ,无显著性差异 (P >0 .0 5 )。病灶CT值在术后 30min和术后 6 0d均减低 ,单点治疗组 :治疗前、治疗后 30min及 6 0d的密度值分别为 :(49.6± 6 .2 )Hu ,(40 .5±14.4)Hu和 (35 .2± 3.2 )Hu ;多点治疗组分别为 :(46 .7± 5 .3)Hu ,(37.4± 11.8)Hu ,(35 .1± 2 .3)Hu ,以上均有显著性差异 (P <0 .0 5 )。结论　CT可判定肺癌集束电极射频治疗前后病灶大小变化和密度变化 ,给肺癌射频治疗的预后提供重要参数 ,为重复治疗提供依据     

肝动脉化疗栓塞术联合CT引导下射频消融治疗大肝癌的疗效和安全性

 目的 评价肝动脉化疗栓塞术(transcatheter arterial chemoembolization, TACE)联合CT引导下经皮穿刺射频消融治疗大肝癌的疗效及安全性。方法 回顾性分析52例经穿刺病理或影像学诊断的大肝癌患者临床资料,患者均先行1次TACE术,术后2周复查增强CT,对碘油沉积欠缺的区域在CT导向下进行射频消融治疗,术后复查甲胎蛋白(AFP)、增强MRI或CT评价肿瘤体积缩小及坏死情况,随访时间为12个月。结果 52例 (56个病灶)手术均获得成功。TACE术前病灶最大径为(12.7±2.7)cm,射频术后1个月病灶最大径为(6.1±1.9)cm,肿瘤大小较术前均有不同程度缩小(t=14.416,P<0.05)。TACE术前AFP值为(4156±689)ng/ml,射频术后1个月为(256±178)ng/ml,AFP值明显下降(t=39.485,P<0.05)。其中完全消融(CR)26例,大部分消融(PR)21例,稳定(SD)4例,进展(PD)1例,总体有效率为90.4%,12个月生存率为92.3%。结论 TACE联合CT导向下射频消融治疗大肝癌是一种安全、有效、微创的治疗方法。     

CT导向下经皮肺穿刺瘤体内植入125I粒子治疗老年肺癌的可行性研究

目的 探讨CT导向下经皮肺穿刺瘤体内植入125I粒子治疗老年肺癌的临床价值.方法 46例老年肺癌患者,CT导向下经皮肺穿刺肿瘤内植入125I粒子,术后1、2、3、6个月,观察肿瘤大小的变化判断临床疗效.结果 46例患者,57个病灶,其中7例行2次植入,1例行3次植入,总穿刺次数为76次.术后观察6个月.术后1、2、3、6个月肿瘤治疗有效率(CR+PR)分别为8.77%(5/57)、40.35%(23/57)、89.47%(51/57)、96.49%(55/57).并发气胸6.58%(5/76),咳血19.57%(9/46).于植入后第6个月复查时2例出现粒子丢失,可能是肿瘤缩小,粒子被咳出.结论 CT导向下经皮肺穿刺瘤体内植入125I粒子对老年肺癌患者是一种微创、安全、疗效可靠的治疗手段.     

CT导向下经皮细针穿刺化学消融术治疗肾上腺肿瘤

目的探讨CT导向下经皮细针穿刺化学消融术治疗肾上腺肿瘤的价值。方法CT导向下经皮细针穿刺化学消融术治疗37例肾上腺肿瘤，其中无功能性腺瘤11例、皮质醇腺瘤5例、醛固酮腺瘤7例、转移瘤14例(20个病灶)。病灶瘤径小于3cm者注射无水乙醇治疗，大于3cm者注射50％冰醋酸治疗。结果10个瘤径小于3cm的良性肿瘤治疗后仅残留少许纤维影；16个大于3cm的良性肿瘤均有进行性缩小；8个转移瘤灶缩小1／3以上，5个转移瘤灶治疗后瘤径无变化但瘤体内存在大面积低密度坏死区，7个转移瘤灶有增大并合并其他部位多发转移。全部功能性肾上腺肿瘤治疗后血液中激素水平恢复到正常范围。结论CT导向下经皮细针穿刺化学消融术治疗肾上腺肿瘤是1种效果显著、创伤性小、操作简便的介入方法。     

CT引导下经皮穿刺微波消融治疗老年人巨块型肺癌的疗效

 目的 探讨CT引导下经皮穿刺微波消融治疗老年人巨块型肺癌的疗效。方法 选择2013-03至2015-03在CT引导下经皮微波消融治疗26例不能手术切除的巨块型肺癌患者,所有病例诊断均经术前穿刺病理证实,其中鳞癌18例,腺癌7例,腺鳞癌1例。术后即刻、3、6、12个月复查增强CT,评价肿瘤体积缩小及坏死情况,分别于术前与术后1个月采用KPS评分评价患者生存质量,随访时间为12个月。结果 26例32次微波手术均获得成功,其中6例于术后1周行二次微波消融手术。微波消融治疗结束后即刻行CT增强扫描,其中CA 5例(19.2%),PA19例(73.1%),SD 2例(7.7%),总体有效率为92.3%。所有患者瘤体负荷显著减轻,治疗前KPS评分为78.23±11.54,治疗后1个月KPS评分为85.13±10.22(t=-2.282,P＜0.05);消融术前肿瘤最大径为(10.4±1.3)cm,消融术后3、6、12个月肿瘤最大径分别为(7.6±2.4)cm、(6.2±2.8)cm 和(5.7±2.5)cm,与术前比较,差异有统计学意义(F=21.482,P＜0.05)。结论 CT引导下经皮穿刺微波消融治疗老年人巨块型肺癌是一种安全、微创、减瘤效果显著的介入方法,其远期疗效和对患者生存期的影响还有待进一步研究。     

CT引导下经皮冷冻消融治疗肺磨玻璃结节的研究

目的 评价CT引导下经皮冷冻消融治疗肺磨玻璃结节的安全性和可行性.方法 2016年6月至2019年11月,28例肺磨玻璃结节患者中有13例为既往肺癌患者,15例为疑是肺肿瘤患者,共35枚结节,平均大小1.04 cm.患者接受了CT引导下同步穿刺活检及经皮冷冻消融,评估冷冻消融后的不良事件、肺功能和治疗效果.使用SPSS...     

CT-guided conformal cryoablation for peripheral NSCLC: Initial experience

Purpose

To study the feasibility of CT-guided and monitored percutaneous conformal cryoablation of Non-Small Cell Lung Cancer for patients who are not suitable for surgical resection.

Materials and method

CT-guided percutaneous conformal cryoablation was performed on 46 patients with peripheral Non-Small Cell Lung Cancer. Patients with tumor sizes less than 3 cm in diameter were treated with double-needle clamping cryoablation, while the patients with 3–5 cm tumor sizes were treated with multiple-needle conformal cryoablation. CT was used to monitor the extent of cryoablation during the procedures. At month 1, 3, 6, 12, and 24 post-procedure, enhanced CT scans and/or PET-CT scans were performed to evaluate the impact of the therapy.

Results

The average tumor CT values were 32 ± 10 HU and −21 ± 8 HU before and after cryoablation, respectively. The largest diameters of the lesions at month 1, 3, 6, 12, and 24 post-procedure were 2.63 ± 0.56 cm, 1.93 ± 0.51 cm, 1.55 ± 0.39 cm, 1.43 ± 0.40 cm, and 1.38 ± 0.38 cm, respectively, in patients with tumor diameter less than 3 cm, and 3.63 ± 0.39 cm, 2.98 ± 0.31 cm, 2.62 ± 0.32 cm, 2.54 ± 0.34 cm, and 2.56 ± 0.37 cm respectively in patients with the tumor diameters between 3 and 5 cm. At the 24th month, there were 36 cases of complete response (83.7%), 7 cases of partial response (16.3%), and no cases of stable disease or progressive disease. 3 patients died due to multiple metastases.

Conclusion

CT-guided percutaneous conformal cryoablation is a safe, effective, and minimally invasive therapeutic method for peripheral lung cancer.     

CT引导下乙醇消融术治疗肝转移瘤

目的 探讨CT引导下无水乙醇消融术(PEI)在肝转移性肿瘤治疗中的价值.方法 53例肝转移性肿瘤,共计87个病灶.18个病灶直径≤1 cm;56个病灶直径1～3 cm;13个病灶直径3～5 cm.采用CT引导下无水乙醇瘤内注射进行治疗,经过1次或多次治疗,观察肝转移瘤的坏死情况.结果 PEI治疗后1个月MR或CT复查,18个直径≤1 cm的病灶完全坏死率为100%;直径1～3 cm 56个病灶完全坏死率为87.5%,再次治疗后完全坏死;13个病灶直径3～5 cm的病灶完全坏死率为61.5%,经过2～3次治疗,病灶彻底坏死.结论 CT引导下无水乙醇消融术治疗肝转移性肿瘤疗效满意,尤其适用于直径≤3 cm的单个病灶.     

氩氦刀冷冻治疗肺癌的CT影像学分析

目的:分析氩氦刀靶向治疗肺癌的CT影像学征象及临床意义。方法:选择16例肺部肿瘤患者,在CT引导下,应用氩氦刀微创、靶向冷冻治疗,并分析其影像学表现特点。结果:氩氦刀冷冻形成的冰球能达到覆盖病灶体积的90%~100%,术前、术中和术后有不同的CT影像学表现。治疗后1~3月复查CT,肿块均有较大程度的缩小或消失。结论:CT影像学表现能够直接客观地评价氩氦刀治疗肺部肿瘤的临床意义及预后。     

Factors affecting diagnostic accuracy of CT-guided coaxial cutting needle lung biopsy: retrospective analysis of 631 procedures

PURPOSE: To analyze variables affecting diagnostic accuracy of computed tomography (CT)-guided percutaneous coaxial cutting needle biopsy of lung lesions. MATERIALS AND METHODS: A retrospective analysis of factors affecting diagnostic accuracy of CT-guided percutaneous coaxial cutting needle lung biopsy was performed in 631 consecutive procedures with confirmed final diagnoses. Benign and malignant needle biopsy results were cross-examined with correct and incorrect final outcomes to determine diagnostic accuracy. Factors affecting diagnostic accuracy were determined by multivariate logistic regression analysis of variables thought to affect diagnostic accuracy. A P value less than 0.05 was interpreted as statistically significant. RESULTS: The overall diagnostic accuracy of CT-guided percutaneous coaxial cutting needle biopsy of lung lesions was 95% (95% CI: 92.7%-96.2%). Sensitivity was 93%, specificity 98%, negative predictive value 6%, positive predictive value 99%, false-positive rate 0.7%, and false-negative rate 15%. The factors affecting diagnostic accuracy were final diagnoses (benign, 86%; malignant, 99%; chi(2) test, P < 0.001) and lesion size (lesions <1.5 cm, 84%; lesions 1.5-5.0 cm, 96%; lesions >5 cm, 93%; chi(2) test, P = 0.06). CONCLUSION: Benign lung lesions, lung lesions smaller than 1.5 cm (which pose technical difficulty), and lung lesions larger than 5 cm (which are associated with a higher necrosis rate) affect diagnostic accuracy of CT-guided percutaneous coaxial cutting needle biopsy of lung lesions.     

125I粒子植入治疗宫颈癌放疗后复发腹膜后淋巴结转移10例

目的 探讨CT引导下放射性125I粒子植入治疗宫颈癌放疗后复发腹膜后淋巴结转移初步疗效.方法 选取2011年11月至2015年10月宫颈癌放疗后复发腹膜后淋巴结转移10例患者,12个病灶,垂直径1.7 cm×1.0 cm～6.5 cm×5.0 cm,其中直径＜5.0 cm、≥5.0 cm的淋巴结分别为6个(50％)、6个(50％).应用近距离治疗计划系统(TPS)制定治疗计划,CT引导下植入125I粒子,活度0.3～0.7 mCi,术后验证D90(90％靶体积所接受的最小剂量):36～110 Gy(中位59 Gy).术后观察病灶大小变化、疼痛缓解情况及并发症.结果 10例患者随访时间4.3～16.1个月,中位随访时间9.7个月,2个月局部控制率100％、有效率58.3％,2、6、12个月生存率分别为100％、66.7％、58.3％,中位生存时间12.1个月.1例患者术后5个月死于消化道出血,6例死于肿瘤转移,3例患者生存并未见粒子植入部位复发,未见其他部位大出血、肠道感染、骨髓抑制等粒子相关严重并发症.结论 CT引导下125I粒子植入治疗宫颈癌放疗后复发腹膜后淋巴结转移取得了较满意的近期疗效,是一种安全可行的方法.     

Percutane Image-Guided Cryoablation of Painful Osseous Metastases: A Retrospective Single-Center Review

PurposePainful osseous metastases are a common problem in patients with malignancy, and they can be associated with significant morbidity owing to immobility, pain, pathologic fracture, or neurovascular compromise or all of these. We retrospectively evaluated pain levels and tumor enhancement in patients who underwent palliative percutaneous cryoablation for painful bone metastasis.MethodsIn this institutional review board-approved, health insurance portability and accountability act-compliant study, we retrospectively searched our department׳s picture archiving system for patients who underwent computed tomography (CT)-guided percutaneous cryoablation for treatment of painful metastatic osseous disease over a 6-year period (1/1/2005-12/31/2011). The preprocedure and postprocedure images and imaging reports, primary tumor type, CT-guided cryoablation procedure details, treated tumor response, immediate and 3-month postprocedure complications, reported pain response to cryoablation, postprocedural tumor imaging characteristics, and imaging response of noncryoablated systemically treated metastatic lesions were reviewed in patients with metastatic osseous disease who underwent cryoablation.ResultsAll 16 patients reported improvement in pain within 1 week after the procedure and at 3-month clinical follow-up. A total of 6.2% had tumor growth and 93.8% had tumor arrest or shrinkage on follow-up CT, although all study patients had progression of noncryoablated metastases at other sites despite systemic therapy. A total of 62.5% of patients with posttreatment contrasted CT demonstrated marginal enhancement at the ablation site, although only single patient had interval growth.ConclusionMost of our patients had tumor arrest or shrinkage on follow-up imaging, despite progression of noncryoablated metastases treated with preprocedure and postprocedure systemic therapy. Radiation therapy, chemotherapy, and analgesics have a moderate failure rate and require repeat treatments where quality of life is the foremost objective. CT-guided cryoablation is a safe palliative treatment to reduce pain in patients with painful osseous metastatic disease, achieve effective local tumor control, and in some cases, provide a curative option for a target lesion.     

冷冻消融治疗复发性盆腔和后腹肿瘤的应用

目的 探索CT定位经皮冷冻消融盆腔和后腹膜术后复发性肿瘤的安全性及疗效.方法 CT定位、引导经皮冷冻消融盆腔、后腹膜恶性肿瘤患者108例并作总结.结果 ①100例中9例为完全性冷冻消融,91例为姑息性冷冻消融.随访3～11年,1年生存率87％(87/100),3年生存率17％(17/100),5年生存率9％(9/100).冷冻后疼痛缓解率84％(70/83).②冷冻后1个月增强CT显示9例完全性消融:肿瘤冷冻区无强化.91例姑息性消融:消融率＞90％ 48例、80％～90％ 25例、70％～80％ 12例、60％～70％4例、＜60％3例.③并发症:术后局部感染3例,抗感染治疗后痊愈;直肠上段肠瘘1例,经肠造瘘后逐渐痊愈;术后短暂排尿困难5例,留置导尿3～5 d恢复;术后发热3～5 d;表皮冻伤3例,对症处理痊愈.结论 盆腔和后腹膜肿瘤术后局限性复发,CT引导冷冻消融较为安全,完全冷冻消融后对提升肿瘤局部控制,延长生存期获益明显.     

CT导引下穿刺活检对胰腺占位性病变的诊断价值

目的 探讨CT导引穿刺活检胰腺占位性病变的诊断价值.方法 回顾性分析CT导引细针穿刺胰腺占位性病变68例,其中胰头区病变49例、胰体12例和胰尾7例.病灶直径2～7 cm,<3cm 10例,3～7 cm 58例.术前均作CT平扫和增强扫描,均采用前路进针,使用20 G细针穿刺.活检标本送病理科作组织病理检查.结果 68例患者均安全地穿刺到病变内,活检成功率为100%.穿刺活检诊断率为恶件病变46例,良性17例,5例未见病变.5例中2例经临床和CT随访均无异常,另3例最终证实胰腺囊腺癌2例和胃癌转移1例.穿刺活检总正确率、灵敏度和特异度分别为96%、95%和100%.CT导引活检对恶性、良性病变的正确率为94%和100%(P>0.05).较大肿块病灶(≥3.0 cm 97%,<3 cm90%)和病变位于胰尾(胰尾100%,胰头96%,胰体92%)的正确率稍高,但经统计学检验正确率差异并无统计学意义(P>0.05),未发现严重的并发症.结论 CT导引经皮细针穿刺活检胰腺占位性病变是一种安全的有效的诊断和鉴别诊断的方法.     

CT引导下经皮穿刺氩氦刀靶向冷冻治疗肾癌

目的初步建立氩氦超导手术系统(简称氩氦刀)靶向冷冻治疗肾癌的技术和探讨其原理、安全性及近期疗效。方法7例肾癌患者采用氩氦刀,在CT引导下经皮穿刺对肿瘤病灶行冷冻治疗。结果7例患者冷冻治疗后未出现出血、皮肤冻伤、感染或穿刺道种植转移等严重并发症。7例在冷冻治疗后1个月,CT显示病灶区内出现低密度坏死区,5例肿瘤大小无改变,2例瘤体有不同程度缩小。结论CT引导经皮穿刺氩氦刀冷冻治疗肾癌是一种安全、有效、微创治疗,特别是对于不能行手术切除的肾癌病例。     

Accuracy of CT-guided transthoracic needle biopsy of lung lesions: Factors affecting diagnostic yield

PURPOSE: This study was performed to analyse the variables affecting the diagnostic accuracy of computed tomography (CT)-guided transthoracic needle biopsy of pulmonary lesions. MATERIALS AND METHODS: A retrospective study of 612 consecutive procedures with confirmed final diagnoses was undertaken. Benign and malignant needle biopsy results were compared with final outcomes to determine diagnostic accuracy. A statistical analysis of factors related to patient characteristics, lung lesions and biopsy technique was performed to determine possible influences on diagnostic yield. A p value less than 0.05 was interpreted as statistically significant. RESULTS: There were 508 (83%) malignant and 104 (17%) benign lesions. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy for a diagnosis of malignancy were 90.2%, 99.0%, 99.8%, 67.3% and 91.7%, respectively. Overall diagnostic accuracy was 83.3%. Variables affecting diagnostic accuracy were the final diagnosis (benign 67%, malignant 92%; p<0.001) and lesion size (lesions<1.5 cm 68%, lesions 1.5-5.0 cm 87%, lesions>5 cm 78%; p<0.05). CONCLUSIONS: In CT-guided transthoracic needle biopsy, the final diagnosis and lesion size affect diagnostic accuracy: benign lung lesions and lesions smaller than 1.5 cm or larger than 5.0 cm in diameter provide lower diagnostic yield.